CA19-9 serum concentrations - Analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1869-1874

  Klapdor, R ^a   Bahlo, M ^a   Babinski, A ^a   Klapdor, S ^a  

^a ZeTDT GmbH   (Germany)

Author keywords

CA19 9; Overall survival; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; AGED; BLOOD LEVEL; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; FOLLOW UP; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; DISEASE-FREE SURVIVAL; HUMANS; KINETICS; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954609004     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Haas M, Boeck S, Stieber P, Laubender RP, Buchner H, Klose C, Kullmann F, Ostermaier S, Bruns CJ, Mansmann U and Heinemann V: The predictive role of CA 19-9 kinetics doe time-to-progression (TTP) and overall survival (OS) in patients (PTS) receiving palliative first-line chemotherapy for advanced pancreatic cancer (PC). Anticancer Res 28(6B): 4015, 2008.
2. Klapdor R: Arbeitsgruppe Qualitätskontrolle und Standardisierung von Tumormarkertestsim Rahmen der Hamburger Symposien über Tumormarker. Tumordiagn Ther 13: XIX-XXH, 1992.
3. EGTM - Consensus Recommendations. Anticancer Res 19: 2785-2820, 1999.
4. Klapdor R, Seutter E, Lang-Pölkow EM, Reichle H and Hinrichs A: Locoregional/sytemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination for mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumromarkers. Anticancer Res 19: 2459-2469, 1999.
5. Burns HA, Moore MJ, Andersen J, Grreen MR, Rothenburg MJ, Modiano MR, Gripps MC; Portenay RK, Storniolo AM, Rarasoff P, Nelson R, Dorr A, Stephens CD and von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
6. Klapdor R, Martini-Svendsen R, Seutter R and Fenner C: Combination therapy with oxaliplatin+gemcitabine in advanced pancreatic cancer. Abstract 576, ECCO 10, Proceedings.
7. Klapdor R, Müller Chr, Seutter R, Bahlo M, Peters W and Fenner C: Improvement of survival by efficacy orintated sequential polychemotherapy of exocrine pancreatic cancer. Anticancer Res 20: 5201-5208, 2000.
8. Klapdor R, Bahlo M, Babinski A and Brenzinger ML: Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer. Anticancer Res 27: 1789-1794, 2007.
9. Ardalan B and Tinn E: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leukovorin in colorectal carcinoma. J Clin Oncol 9: 625-630, 1991.
10. Grothey A, Deschler B and Kroening H: Phase III study of bolus 5-fluorouracil (5FU)/folinic acid (FA) vs. weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer(ACRC). Proc Am Soc Clin Oncol 21: 129a, 2002 (abstr 512).
11. Pelzer U, Stieler J, Roll L, Hilbig A, Dörkern B, Riess H and Oettle H: Second-line therapy in refractory pancreatic cancer. Onkologie 32(3): 99-102, 2009.
12. Adler G, Seufferlein T, Bischoff SC, Brambs H, Feuerbach S and Grabenbauer G: S3-Leitlinie "exkretorisches Pankreaskarzinom", Z. Gastroenterol 45(6): 487-523, 2007.